Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera

Sofia Casares, Alicia Hurtado, Robert C. McEvoy, Adelaida Sarukhan, Harald von Boehmer, Teodor Doru Brumeanu

Research output: Contribution to journalArticlepeer-review

106 Scopus citations

Abstract

Type I diabetes is an organ-specific autoimmune disease that is mediated by autoreactive T cells. We show here that administration of a soluble dimeric peptide-major histocompatibility complex (pMHC) class II chimera (DEF) to prediabetic double-transgenic mice prevents the onset of disease or, in animals that are already diabetic, restores normoglycemia. The antidiabetogenic effects of DEF rely on the induction of anergy in splenic autoreactive CD4+ T cells via alteration of early T cell receptor signaling and stimulation of interleukin 10-secreting T regulatory type I cells in the pancreas. Soluble dimeric pMHC class II may be useful in the development of immunospecific therapies for type I diabetes.

Original languageEnglish
Pages (from-to)383-391
Number of pages9
JournalNature Immunology
Volume3
Issue number4
DOIs
StatePublished - Apr 2002

Fingerprint

Dive into the research topics of 'Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera'. Together they form a unique fingerprint.

Cite this